Acute Myeloid Leukemia

AML diagnosis and classification require integrated morphologic, immunophenotypic, cytogenetic, and molecular assessment. The 2022 European LeukemiaNet (ELN) recommendations incorporate contemporary genetic classification into diagnostic reporting, risk stratification, response assessment, and treatment planning. ScienceDirect+1ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

At presentation, obtain peripheral-blood and bone-marrow evaluation sufficient for morphology, multiparameter flow cytometry, conventional cytogenetics, and molecular testing. Molecular results influence prognostic assignment and may identify therapies directed at FLT3 and other actionable genomic lesions; treatment decisions should be updated as delayed molecular results return. ScienceDirect+1ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

Do not allow a single baseline risk label to substitute for longitudinal reassessment. Cytogenetic and molecular findings, remission depth, measurable residual disease (MRD), treatment tolerance, and transplant eligibility each modify the post-remission strategy. ScienceDirect+1ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

The updated ASH guideline addresses newly diagnosed AML in older adults and emphasizes evidence-based choices among available low-intensity therapies. Older adults are heterogeneous; conventional intensive induction may be inappropriate for some patients, but age alone does not define treatment ineligibility. ScienceDirect+1ScienceDirectAmerican Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsWolters KluwerNew Clinical Practice Guidelines on AML in Older Adults

For a patient considered for intensive therapy, integrate functional status, comorbidity, organ reserve, performance status, adverse disease biology, expected treatment-related toxicity, transplant candidacy, and patient preferences. For a patient not considered eligible for intensive therapy, choose a regimen with an achievable outpatient or inpatient delivery plan, explicit transfusion and infection support, and an early response-assessment strategy. ScienceDirect+3ScienceDirectAmerican Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNWolters KluwerNew Clinical Practice Guidelines on AML in Older AdultsASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

Genomic risk is clinically consequential because ELN recommendations use genetic findings to categorize prognosis and guide consideration of allogeneic hematopoietic cell transplantation (HCT) in first remission. Risk should be interpreted alongside response quality rather than as an immutable designation. ScienceDirect+1ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

For patients ineligible for intensive chemotherapy, venetoclax combined with a hypomethylating agent or low-dose cytarabine has prospective clinical-trial support. A phase 3 trial evaluated venetoclax plus low-dose cytarabine in newly diagnosed AML among patients ineligible for intensive chemotherapy, and prospective studies have evaluated venetoclax with azacitidine or decitabine. ASCOASCOContemporary Approach to Acute Myeloid Leukemia Therapy in 2022

Venetoclax administration requires active medication reconciliation because antifungal agents can alter venetoclax elimination through CYP3A-related interactions. Interaction management is especially important because azole antifungal prophylaxis is commonly considered during prolonged neutropenia. ASCOASCOConsensus-Based Guidelines for Acute Myeloid Leukemia ...

Targeted therapies have expanded AML options, and the ELN treatment recommendations incorporate targeted agents into intensive and nonintensive treatment pathways. Actual regimen selection should be based on the detected lesion, regulatory status, intended treatment backbone, prior therapy, organ function, drug interactions, and local leukemia-program protocols. The supplied evidence does not support specifying U.S. product-label doses in this review. ScienceDirect+2ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of HematologyASCOContemporary Approach to Acute Myeloid Leukemia Therapy in 2022

The ELN recommendations identify MRD as a central biomarker in AML response assessment and provide guidance on its role in clinical decision-making. MRD assessment may use molecular methods when a suitable marker is present or multiparameter flow cytometry when an appropriate leukemia-associated immunophenotype can be tracked. ScienceDirect+1ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

Interpret MRD in context. Assay sensitivity, specimen quality, the stability and specificity of the molecular marker, treatment timing, and concordance with morphology and blood-count recovery all affect meaning. A detectable or rising MRD signal generally indicates higher relapse risk, but management should be individualized rather than driven by an isolated result without considering assay and clinical context. ScienceDirect+1ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

Post-remission therapy should be planned before remission is documented. ELN guidance addresses consolidation, maintenance therapy, and timing of allogeneic HCT; the choice depends on genetic risk, remission depth, MRD, prior treatment, patient fitness, donor options, and patient preferences. ScienceDirect+1ScienceDirectDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNASHDiagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology

AML treatment frequently produces prolonged cytopenias and requires a coordinated support plan for blood products, infection evaluation, antimicrobial strategy, metabolic monitoring, and urgent symptom escalation. Low-intensity venetoclax-based regimens also require close surveillance because clinically consequential cytopenias and drug interactions can occur outside the inpatient setting. ASCO+1ASCOContemporary Approach to Acute Myeloid Leukemia Therapy in 2022ASCOConsensus-Based Guidelines for Acute Myeloid Leukemia ...

Medication review should be repeated whenever prophylactic antimicrobials or other new drugs are started, stopped, or changed. CYP3A-related interactions with venetoclax are particularly relevant when antifungal therapy is used. ASCOASCOConsensus-Based Guidelines for Acute Myeloid Leukemia ...

Care planning should include early goals-of-care discussions alongside disease-directed treatment. For older adults and patients with substantial comorbidity, shared decisions about intensity, expected toxicities, hospitalization, transfusion support, and time at home are integral to appropriate AML management. ScienceDirect+1ScienceDirectAmerican Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsWolters KluwerNew Clinical Practice Guidelines on AML in Older Adults